(RTTNews) - GRI Bio, Inc. (GRI), a biotechnology company, Tuesday announced that it has regained compliance with Nasdaq's minimum bid price rule. The company received official notice from The ...

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on ...

Our reports adhere to global reporting standards and best practices. Collectively, the World Bank Sustainability Review, Global Reporting Initiative (GRI) Index, Annual Report, Climate-related ...

GRI Bio (GRI) received notice on March 10, 2025 from The Nasdaq Stock Market stating that the Company regained compliance with Nasdaq Listing ...